Best in Biotech 31 Dec 2018 European Biotech’s Biggest News of 2018 …Lundbeck paying up to €900M in March for the Swiss biotech Prexton Therapeutics, which is developing a drug for Parkinson’s disease. Then there were the big deals and collaborations. Genentech… December 31, 2018 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 May 2023 Five recent advancements in arthritis research over the past year …conditions like Parkinson’s better, studying the oral microflora further, could be crucial in effectively treating gum diseases as well as rheumatoid arthritis. New drug could stop osteoarthritis from getting out… May 22, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Oct 2025 Five latest advancements in Tourette’s syndrome research …brain stimulation (DBS) has paved the way for transformative treatment approaches for Parkinson’s disease. DBS involves the implantation of electrodes in certain regions of the brain where electrical impulses are… October 20, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2018 A Crash Course in the Basics of Finance in Biotechnology …might be switching from the first market approval of a CAR-T therapy to the latest strategy to protect crops from pests to a new anti-Parkinson’s drug. It can be hard… January 4, 2018 - 5 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2023 Gene therapy company EG 427 raises €18M …or other neurodegenerative diseases such as multiple sclerosis or Parkinson’s disease. Pierre Denys, head of Urology department at R. Poincaré Hospital in Paris and co-founder of EG 427, said: “Neurogenic… July 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2021 Danish Dementia Startup Launches Amid Maturing Nordic Biotech Scene …treatments for Parkinson’s disease, multiple sclerosis, and frontotemporal dementia. Research in Alzheimer’s disease and in other neurodegenerative diseases has picked up in recent months, after a tough streak of more… July 20, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2025 Vandria reports VNA-318’s first-in-human data in Alzheimer’s …toward Parkinson’s and mitochondrial disorders. Overall, while there is genuine scientific momentum behind mitophagy as a neuroprotective strategy, very few efforts have combined mitophagy-enhancing chemistry, brain penetration, and an explicit… December 2, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Sanofi sells two portfolios of established products to Neuraxpharma …across a large spectrum of diseases including depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson disease. The CNS portfolio notably includes Nozinan, Tranxene, Tiapridal, Dogmatil, Largactil. The pain and… July 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 28 Oct 2022 Migraines: a new vaccine frontier beyond infectious diseases …vaccines for chronic conditions such as migraines, Alzheimer’s and Parkinson’s — to name a few. By combining the power of mAbs and the convenience and affordability of vaccines, Vaxxinity’s synthetic… October 28, 2022 - 7 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Jul 2025 14 biotech companies to know in the Boston area in 2025 …targeting neuroinflammation in Parkinson’s disease. Orna Therapeutics Founded: 2019 Focus area: Circular RNA therapies Lead candidate: In vivo CAR-T Orna Therapeutics is developing therapies using circular RNA, an alternative to… July 4, 2025 - 15 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 …loss in the brain. LMTX also inhibits the aggregation of TPD-43 (behavioral variant frontotemporal dementia), synuclein (Parkinson’s disease), and huntingtin proteins (Huntington’s disease). With 2016’s biggest fundraising round of €120M… February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 May 2024 Eight monoclonal antibody biotechs making strides in the clinic …BioArctic looks to counter is Parkinson’s disease. Its phase 1 candidate exidavenmab is a monoclonal antibody that binds to toxic forms of alpha-synuclein – a protein that can cause inflammation… May 2, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email